• By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.
OK
Search
Skip to main content
Advertisement

Boehringer Ingelheim

  1. Business
  2. Pharmaceuticals
  3. Boehringer Ingelheim
IBM wants to use its AI to help new antibody discoveries TechRadar Pro04:48AI IT Pharma
Boehringer Ingelheim swaps lab coats for AI algorithms in search for new drugs The Register13:04AI IT Pharma
Boehringer Ingelheim announces acquisition of T3 Pharmaceuticals Pharmaceutical Business Review06:09Pharma Biotechnology
Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m PMLiVE07:31Pharma Biotechnology
Boehringer Ingelheim acquires immunotherapy biotech T3 Pharmaceuticals for $507M ENDPOINTS12:37Cancer Treatment Biotechnology Pharma
Boehringer buys cancer immunotherapy firm T3 for $507m pharmaphorum11:32Cancer Treatment Biotechnology Pharma
BI-765179 by Boehringer Ingelheim international for transitional cell carcinoma (urothelial… Pharmaceutical Technology21:58Cancer Treatment Cancer Pharma
BI-765179 by Boehringer Ingelheim international for malignant pleural mesothelioma: Likelihood… Pharmaceutical Technology21:58Cancer Treatment Cancer Pharma

Latest News

In the last 7 days
Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario BioSpace00:22 8-Dec-23
Palmoplantar Pustulosis Market to Grow significantly by 2032 | Kyowa Kirin Co., Ltd, Amgen,… Industry Today09:24 7-Dec-23
Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim PR Newswire (Press Release)07:36 6-Dec-23
CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for… GlobeNewswire (Press Release)05:11 6-Dec-23
BI-765179 by Boehringer Ingelheim International for Transitional Cell Carcinoma (Urothelial… Pharmaceutical Technology21:58 5-Dec-23
BI-765179 by Boehringer Ingelheim International for Malignant Pleural Mesothelioma: Likelihood… Pharmaceutical Technology21:58 5-Dec-23
BI-765179 by Boehringer Ingelheim International for Solid Tumor: Likelihood of Approval Pharmaceutical Technology21:58 5-Dec-23
BI-765179 by Boehringer Ingelheim International for Hepatocellular Carcinoma: Likelihood of… Pharmaceutical Technology21:58 5-Dec-23
BI-765179 by Boehringer Ingelheim International for Gastric Cancer: Likelihood of Approval Pharmaceutical Technology21:58 5-Dec-23
BI-765179 by Boehringer Ingelheim International for Pancreatic Cancer: Likelihood of Approval Pharmaceutical Technology21:58 5-Dec-23
BI-765179 by Boehringer Ingelheim International for Melanoma: Likelihood of Approval Pharmaceutical Technology21:58 5-Dec-23
BI-765179 by Boehringer Ingelheim International for Cervical Cancer: Likelihood of Approval Pharmaceutical Technology21:58 5-Dec-23
BI-765179 by Boehringer Ingelheim International for Colorectal Cancer: Likelihood of Approval Pharmaceutical Technology21:58 5-Dec-23
BI-765179 by Boehringer Ingelheim International for Ovarian Cancer: Likelihood of Approval Pharmaceutical Technology21:58 5-Dec-23
In the last month
Boehringer Ingelheim buys Swiss oncology firm T3 Pharma Chemical & Engineering News19:44 2-Dec-23
IBM wants to use its AI to help new antibody discoveries TechRadar Pro04:48 2-Dec-23
Boehringer Ingelheim swaps lab coats for AI algorithms in search for new drugs The Register13:04 1-Dec-23
IBM, Boehringer partner on genAI, foundation models for therapeutic antibody research MobiHealthNews16:33 30-Nov-23
Boehringer Ingelheim and IBM team up to make antibodies with generative AI ENDPOINTS14:37 29-Nov-23
Boehringer Ingelheim Targets Stroma-Rich Cancers in Potential $509M AI Deal BioSpace11:13 29-Nov-23
Phenomic Enters Strategic Collaboration with Boehringer Ingelheim to Discover Novel Targets for … Business Wire (Press Release)08:05 29-Nov-23
Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership PMLiVE07:46 29-Nov-23
Stop Rabies White Paper, Boehringer Ingelheim In Support Of 'Zero By 30' Global Goal Bernama22:19 28-Nov-23
Boehringer Ingelheim and IBM Collaborate to Advance Generative AI and Foundation Models for Therapeutic Antibody… IBM (Press Release)03:07 28-Nov-23
Boehringer Ingelheim announces acquisition of T3 Pharmaceuticals Pharmaceutical Business Review06:09 24-Nov-23
Boehringer Ingelheim to advance bacterial cancer therapeutics European Pharmaceutical Review10:59 23-Nov-23
Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m PMLiVE07:31 23-Nov-23
Boehringer Ingelheim acquires T3 Pharma for $509m Pharmaceutical Technology06:50 23-Nov-23
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid… Business Wire (Press Release)02:35 23-Nov-23
Boehringer Ingelheim Buys Swiss Biotech Company T3 Pharma for $509 Mln MarketWatch12:37 22-Nov-23
Boehringer Ingelheim acquires immunotherapy biotech T3 Pharmaceuticals for $507M ENDPOINTS12:37 22-Nov-23
Boehringer buys cancer immunotherapy firm T3 for $507m pharmaphorum11:32 22-Nov-23
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer … Business Wire (Press Release)11:01 22-Nov-23
German pharma company acquires University of Basel start-up for 450 million Swiss francs University of Basel08:16 22-Nov-23
Boehringer Ingelheim Expands Usage of Genedata Biologics to DMPK Operations PRWeb (Press Release)08:33 20-Nov-23
BI-1358894 by Boehringer Ingelheim International for Major Depressive Disorder: Likelihood of… Pharmaceutical Technology12:51 18-Nov-23
BI-765049 by Boehringer Ingelheim International for Hepatocellular Carcinoma: Likelihood of… Pharmaceutical Technology22:56 17-Nov-23
BI-765049 by Boehringer Ingelheim International for Pancreatic Cancer: Likelihood of Approval Pharmaceutical Technology22:56 17-Nov-23
Major Depressive Disorder Market to Register Stunning Growth During the Forecast Period (2023–2032), Examines… GlobeNewswire (Press Release)13:02 16-Nov-23
UofG spin-out Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant … University of Glasgow01:40 14-Nov-23
Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting… Business Wire (Press Release)19:04 13-Nov-23
Plenty Of Room For More Obesity Drugs, Says Boehringer, As Survodutide Enters Phase III Scrip Pharma Intelligence12:31 10-Nov-23
How Boehringer Ingelheim and Pfizer battled over the exclusivity of the first Humira interchangeable ENDPOINTS14:09 9-Nov-23
view more headlines
8 Dec 00:22

Boehringer News

NewsNow aims to be the world's most accurate and comprehensive aggregator of Boehringer news, covering the latest share price, company announcements, product trials, pharmaceuticals news and more from the best online publications. Every story from every site is brought to you automatically and continuously 24/7, within around 10 minutes of publication.
Read more

Pharmaceuticals Top Stories

US agency approves cure for Sickle Cell Disease Leadership, Nigeria16:17CRISPR/Gene Editing FDA Business (US)
U.S. FDA approves two gene therapies for sickle cell disease CTV News Edmonton12:11CRISPR/Gene Editing FDA Business (US)
US approves CRISPR gene-editing to treat sickle cell disease Deutsche Welle14:55CRISPR/Gene Editing FDA
FDA approves two gene therapies for sickle cell, bringing hope to thousands with the disease WHDH-TV, Massachusetts14:11CRISPR/Gene Editing FDA
AbbVie buys Cerevel Therapeutics for $8.7B, Bolstering neuroscience portfolio Investopedia15:29AbbVie Biotech Cerevel Therapeutics
AbbVie to acquire Cerevel Therapeutics for $8.7 Billion European Pharmaceutical Manufacturer05:48AbbVie Biotech Cerevel Therapeutics
New sickle cell Drug awaiting FDA approval met with mixed emotions Black Enterprise10:03CRISPR/Gene Editing FDA
FDA approves two sickle cell therapies, including the first CRISPR medicine The Guam Daily Post09:15CRISPR/Gene Editing FDA
Merck-Eisai uterine cancer drug combination fails first-line treatment study Proactive Investors (US)09:37Keytruda Merck & Co Eisai
MSD’s Keytruda and Eisai’s Lenvima fail in Phase III uterine cancer trial Pharmaceutical Technology09:34Keytruda Merck & Co Eisai

Business Top Stories

The S&P 500 just had 1 of its best months in history. Here's what the stock market usually does next The Motley Fool09:54Dow Jones S&P 500 Nasdaq
Be careful what you wish for: This event may signal the start of the 2024 bear market The Motley Fool05:09Dow Jones S&P 500 Nasdaq
Elon Musk reactivates Alex Jones' X accounts after a five-year ban CNBC09:47X (Twitter) Elon Musk Alex Jones
Elon Musk’s Grok Twitter AI is actually ‘Woke,’ hilarity ensues Forbes09:27X (Twitter) Elon Musk Alex Jones
Elon Musk says Ilya Sutskever—the OpenAI chief scientist who helped fire Sam Altman then… Yahoo! US07:59Sam Altman OpenAI AI
OpenAI’s Sam Altman was said to be psychologically abusive, Washington Post reports The Messenger11:16Sam Altman OpenAI AI
EU sets global precedent with comprehensive AI regulation deal ReadWriteWeb16:50AI IT ChatGPT
Europe seals world's first set of rules regulating artificial intelligence Fox News12:58AI IT ChatGPT
UPenn President Liz Magill has resigned, but antisemitism remains a problem on college campuses CNN Money06:19Antisemitism Business (US) Politics
The 4 key events that led to UPenn President Liz Magill’s resignation CNN (Video)10:51Antisemitism Business (US) Politics
Publication filters

Headline Density

Notifications

  • Unsubscribe from Breaking News
    Sorry, no headlines or news topics were found. Please try different keywords.